MX2022001151A - Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. - Google Patents
Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.Info
- Publication number
- MX2022001151A MX2022001151A MX2022001151A MX2022001151A MX2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- deuterated
- pathway
- inhibitors
- map kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001151A true MX2022001151A (es) | 2022-02-22 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001151A MX2022001151A (es) | 2019-07-31 | 2020-07-31 | Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12403141B2 (enExample) |
| EP (1) | EP4003344A4 (enExample) |
| JP (1) | JP2022542434A (enExample) |
| KR (1) | KR20220041180A (enExample) |
| CN (1) | CN114206339A (enExample) |
| AU (1) | AU2020319879A1 (enExample) |
| BR (1) | BR112022001324A2 (enExample) |
| CA (1) | CA3149304A1 (enExample) |
| IL (1) | IL290045A (enExample) |
| MX (1) | MX2022001151A (enExample) |
| PH (1) | PH12022550029A1 (enExample) |
| WO (1) | WO2021022186A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220161396A (ko) * | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| EP4367099A4 (en) | 2021-07-09 | 2025-06-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023150709A2 (en) * | 2022-02-04 | 2023-08-10 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| CN119384410A (zh) * | 2022-03-03 | 2025-01-28 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
| EP4650347A1 (en) * | 2023-01-13 | 2025-11-19 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| JP2026504073A (ja) * | 2023-01-13 | 2026-02-03 | プールベグ ファーマ（ユーケー） リミテッド | がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法 |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008141057A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
| JP5466759B2 (ja) * | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| US8575348B2 (en) * | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| SI2648516T1 (sl) * | 2010-12-06 | 2019-01-31 | Aclaris Therapeutics, Inc. | Substituirane spojine piridinon-piridinila |
| HUE054178T2 (hu) * | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| EP3442940A1 (en) * | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| EP3720436A4 (en) | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | TUBULIN INHIBITORS |
| US20230087078A1 (en) | 2020-03-02 | 2023-03-23 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
-
2020
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja not_active Ceased
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en not_active Ceased
- 2020-07-31 PH PH1/2022/550029A patent/PH12022550029A1/en unknown
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt not_active IP Right Cessation
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en active Pending
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en not_active Abandoned
- 2020-07-31 US US17/630,414 patent/US12403141B2/en active Active
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko active Pending
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290045A (en) | 2022-03-01 |
| WO2021022186A1 (en) | 2021-02-04 |
| CA3149304A1 (en) | 2021-02-04 |
| CN114206339A (zh) | 2022-03-18 |
| JP2022542434A (ja) | 2022-10-03 |
| KR20220041180A (ko) | 2022-03-31 |
| EP4003344A4 (en) | 2023-07-26 |
| PH12022550029A1 (en) | 2023-02-27 |
| US20220288070A1 (en) | 2022-09-15 |
| US12403141B2 (en) | 2025-09-02 |
| AU2020319879A1 (en) | 2022-02-03 |
| BR112022001324A2 (pt) | 2022-03-22 |
| EP4003344A1 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001151A (es) | Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. | |
| DOP2025000288A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| CL2022000447A1 (es) | Inhibidores de kras g12d | |
| PH12021550187A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| CL2004002050A1 (es) | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| CR20190332A (es) | Inhibidores selectivos de jak1 | |
| UY27729A1 (es) | Inhibidores de quinasas. | |
| ECSP077985A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| CO2021004789A2 (es) | Piridazinonas y sus métodos de uso | |
| ECSP109953A (es) | Derivados de piridazinona | |
| ECSP034750A (es) | Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| CO2017004517A2 (es) | Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |